Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X, Shi M, Jie F, Bai Y, Shen P, Yu Z, Wang X, Huang C, Tao M, Wang Z, Xie C, Wu Q, Shu Y, Han B, Zhang F, Zhang Y, Hu C, Ma X, Liang Y, Wang A, Lu B, Shi Y, Chen J, Zhuang Z, Wang J, Huang J, Wang C, Bai C, Zhou X, Li Q, Chen F, Yu H, Feng J.
Ouyang X, et al. Among authors: zhou x.
Invest New Drugs. 2018 Apr;36(2):315-322. doi: 10.1007/s10637-017-0536-y. Epub 2017 Nov 14.
Invest New Drugs. 2018.
PMID: 29134432
Clinical Trial.